Adam Cribbs: Against Easy Answers In Single-Cell Biology

SCIENTIFIC SPOTLIGHT
An editorial series by Atrandi Biosciences

In every lab there’s a quieter narrative running alongside the results: the intriguing questions, the workarounds, the moments when a method finally clicks. Scientific Spotlight is a series of editorial profiles of researchers pushing single-cell science forward. We focus on the science, the journey, and the practical realities behind the headlines – what worked, what didn’t, and what changed their trajectory.

Introduction
Few institutions have a longer history of sitting with hard questions than the University of Oxford. Across its colleges and research institutes, it has produced more Nobel laureates than most countries, and a long tradition of scientists who chose the problem over the path of least resistance.

Adam Cribbs, Associate Professor of Computational Genomics and group leader at the Botnar Research Centre, fits that tradition quite perfectly, though he might describe it rather more plainly. “I only work on things that really annoy me,” he says laughing. “Things that I think need to be solved.”

In practice, that means spending over a decade working on some of the most technically demanding and scientifically underexplored corners of single-cell genomics – hard and complex tissues that don’t yield easily to standard methods, long-read sequencing applied at single-cell resolution before the technology was ready, and musculoskeletal diseases that the field, as Adam puts it, simply hasn’t funded enough. It also means building a group that deliberately sits at the intersection of wet lab, computational biology, and machine learning, because, in his view, that intersection is where science actually moves.

Starting from curiosity
Adam’s scientific formation was quantitative before it was biological. He came to his PhD in molecular immunology at the Kennedy Institute of Rheumatology at Oxford with a mathematical orientation and left with a conviction he has carried since – a direct view of what happens when basic science translates into medicine.

The Kennedy Institute was known for the development of anti-TNF therapy. A story that began with fundamental work on TNF biology as a key mediator in inflammatory processes, moved through antibody development and clinical trials, and ended with patients who had been crippled by rheumatoid arthritis running up and down stairs after three weeks on the drug. Adam was there as that story was becoming widely used in the clinic, close enough to see what basic science could do.

“I’ve always been trying to emulate the ability to either identify a mechanism that could lead to novel therapeutics or at least have research that has a much wider global impact,” he says.

Read full story here